We use our own and third-party cookies to offer our services and collect statistical data. If you continue browsing our site, it is understood that you accept said cookies. More information

Accept
Back

BioClever joins REVASCAT ischemic stroke trial

19-04-2017
BioClever joins REVASCAT ischemic stroke trial
On April 17th, the Health Department of the Generalitat of Catalonia introduced the REVASCAT trial, which presented the conclusions on a new revolutionary treatment for ischemic stroke. 
  
BioClever participated in this interesting advance on ischemic stroke by performing eCRFs, data management and statistics.

The study lasted a little over two years, starting in November 2012 and concluding in December of last year, and has been developed in four Catalan hospitals: Vall de Hebron, Clínico, Bellvitge and Germans Trias, with the collaboration of the an> Polytechnic University of Catalonia (UPC) and the University of Pittsburgh (United States), and the participation of other international institutions to develop this clinical trial, a pioneer in the field of brain vascular pathologies. 
  
On this same day, a Catalan delegation that included part of the team of BioClever that participated in the study traveled to Glasgow (Scotland) to explain the results to the world at the European Stroke Organization Conference
  
The results from the REVASCAT trial have also been published in the renowned New England Journal of Medicine, in which the advantages of clearing the affected brain arteries in patients with stroke using next-generation devices introduced with microcatheters are explained. Thanks to this advance, the study concluded that patients affected by this condition and treated with this system have four times more chances to increase their autonomy during daily basic activities, allowing them to improve their quality of life as well as to increase the recovery of their functional capacity by 70%.

The procedure used in the study is highly complex, because it involves reaching very delicate areas of the brain by endovascular navigation and removing the thrombus through a catheter introduced in the femoral artery until the affected area is reached. That is why, it can only be performed in hospitals by highly qualified professionals. With this development, it will be possible to keep reducing the mortality rate of this condition that has such a significant social impact, since in Catalonia it is the first cause of death among women, the third among men, and the first cause of disability.  

Related news

MSL Introductory Course
20-06-2018

MSL Introductory Course

In September, we will host an introductory course in collaboration with The MSL Project, that will be held in Madrid.
Regulations concerning clinical trials with drug products
20-11-2016

Regulations concerning clinical trials with drug products

At the 11th Congress held by the Medical Association of the Pharmaceutical Industry (AMIFE, as per the Spanish acronym), held on November 12-14 in Madrid, one of the issues discussed was the status of the Clinical Trial Royal Decree, which is currently awaiting the ruling of the State Council, since the text is almost finished, as stated by Mr. César Hernández, Head of the Committee on Medicinal Products for Human Use of the Spanish Agency of Medicinal Products and Medical Devices (AEMPS).
Evolution of Data Management in Clinical Research: Clinsight and CDISC.
30-11-2015

Evolution of Data Management in Clinical Research: Clinsight and CDISC.

In the field of clinical research, perhaps one of the areas that has most clearly evolved over the years is data management, particularly with respect to the methods of data collection and database creation and preparation for subsequent analysis while ensuring their integrity and quality at all times.